Skip to content
Home
About Us
Our Goal
Management Team
Board of Directors
Scientific Advisory Board
Technology Platform
The Challenge
Platform
Our Focus
Focus Areas
Pipeline
Osteoporosis
Hypoparathyroidism
Inflammatory Diseases
Strategic Partners
Investors
Share Information
Share Chart
Email Alerts
Press Releases
SEC Filing
Investor Calendar
Corporate Governance
Board of Directors
Management
Committee Composition
Investor Resources
Investor FAQs
Document Request
Email Alerts
Corporate Presentation
News & Events
Contact Us
Menu
Home
About Us
Our Goal
Management Team
Board of Directors
Scientific Advisory Board
Technology Platform
The Challenge
Platform
Our Focus
Focus Areas
Pipeline
Osteoporosis
Hypoparathyroidism
Inflammatory Diseases
Strategic Partners
Investors
Share Information
Share Chart
Email Alerts
Press Releases
SEC Filing
Investor Calendar
Corporate Governance
Board of Directors
Management
Committee Composition
Investor Resources
Investor FAQs
Document Request
Email Alerts
Corporate Presentation
News & Events
Contact Us
Inflammatory
Diseases
Under our 2018 license agreement with Amgen we are developing oral formulations of novel therapeutic protein candidates.
Thank You
Message Sent!
We will get back to you soon
by WildWeb